Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 8, 2004. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and updates regarding directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes and share ownership details.
- Shares Repurchased: 700,000 Ordinary Shares of 25 pence each.
- Repurchase Date: November 5, 2004.
- Price per Share: 1,196.67 pence.
- Treasury Shares Held: 50,678,000 (post-transaction).
- Shares in Issue: 5,885,451,226 (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 700,000 shares for treasury. Additionally, the GlaxoSmithKline US Retirement Savings Plan saw a change in holdings due to fund movements on November 5, 2004.
- Retirement Plan Holdings: Increased from 18,906,115 to 18,925,488 Ordinary Share ADRs.
- Average Price: $44.37.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 700,000 share repurchase (700,000 shares x 1,196.67 pence).
- Confirm the updated total share count excluding treasury shares (5,885,451,226).
- Note that Directors Dr. J.P. Garnier and Dr. T. Yamada have potential indirect interests in the US Retirement Savings Plan holdings.
- Recognize that this filing does not contain operational or financial performance data for the period.